ArticleCirculation. Heart failure2018
Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy.
Article in Circulation. Heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- Mechanical circulatory support as a cornerstone in advanced heart failure and transplantation.Frontiers in cardiovascular medicine · 2025Review
- Cardiogenic Shock in Restrictive Cardiomyopathies: What We Know So Far.US cardiology · 2025Review
- Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies.Current cardiology reports · 2024Review
- ECMO as a bridge to heart transplantation: Insights into stratification by heart failure etiology.JHLT open · 2024Article
- The role of temporary mechanical circulatory support inJournal of intensive medicine · 2023Review
- Theoretical considerations for a left atrial pump in heart failure with preserved ejection fraction.Heart failure reviews · 2023Review
- A case series of cardiac amyloidosis patients supported by continuous-flow left ventricular assist device.ESC heart failure · 2021Article
- Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?Circulation. Heart failure · 2021Article
- Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies.PloS one · 2021Article
- Comparing outcomes for infiltrative and restrictive cardiomyopathies under the new heart transplant allocation system.Clinical transplantation · 2020Article
- Cardiac transplantation for hypertrophic cardiomyopathy in the United States 2003-2011.International journal of critical illness and injury scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundPatients with restrictive cardiomyopathy (RCM) and hypertrophic cardiomyopathy (HCM) generally are considered poor candidates for mechanical circulatory support devices (MCSDs) and often not able to be bridged mechanically to heart transplantation. This study characterized MCSD utilization and transplant waitlist outcomes in patients with RCM/HCM under the current allocation system and discusses changes in the era of the new donor allocation system. METHODS AND
resultsPatients waitlisted from 2006 to 2016 in the United Network for Organ Sharing registry were stratified by RCM/HCM versus other diagnoses. MCSD utilization and waitlist duration were analyzed by propensity score models. Waitlist outcomes were assessed by cumulative incidence functions with competing events. Predictors of waitlist mortality or delisting for worsening status in patients with RCM/HCM were identified by proportional hazards model. Of 30 608 patients on the waitlist, 5.1% had RCM/HCM. Patients with RCM/HCM had 31 fewer waitlist days (
conclusionsPatients with RCM/HCM are less likely to receive MCSD but have similar waitlist mortality and slightly higher incidence of transplantation compared with other patients. The United Network for Organ Sharing RCM/HCM risk model can help identify patients who are at high risk for clinical deterioration and in need of expedited heart transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.